Advertisement

Asia

Calysseo starts production at its first industrial-scale facility in China

The facility will produce 20,000 tonnes of FeedKind® Aqua protein annually and the first material is expected at the turn of the year.

Calysseo starts production at its first industrial-scale facility in China
June 26, 2022

Calysseo, a joint venture between Adisseo and protein innovator Calysta, is commissioning and starting up activities at the world’s first industrial-scale FeedKind® facility in Chongqing, China. The facility will produce 20,000 tonnes of FeedKind® Aqua protein annually.

The microbial protein is produced via a natural fermentation that does not use arable land, animal or plant matter, and uses very little water in its production. Initially, production will be available for use in China, the world’s largest aquaculture market. While operating under COVID-19 restrictions, the Calysseo team maintained the schedule of the landmark facility, meaning FeedKind® should be delivered to the first customers this year.

“This is a significant milestone as we move towards more sustainable forms of making food. Calysseo and FeedKind offer a world first, a newly available sustainable, nutritious, non-GMO protein that offers significant health benefits over other feed ingredients, such as improved gut health and improved immune response,” said Jean-Marc Dublanc, CEO of Adisseo. “We have a long-running commitment to improving the security and sustainability of the feed ingredient market and Calysseo fulfills a significant part of that pledge. We will provide Chinese customers with a reliable, domestically available supply of protein that meets their specific needs, produced in China for China.” 

“Cellular agriculture, where protein is grown in a controlled environment, is key to helping the world meet its future food needs. Today will go down in history as a hugely significant moment in the development and delivery of new, sustainable sources of protein to meet growing, global demand,” said Alan Shaw, co-founder, CEO and president of Calysta. “For Calysta, today is the result of years of work to develop a protein without limits – one that meets our growing demand for protein while protecting biodiversity. It also marks the beginning of a new phase in the Calysta story as we work on producing additional protein ingredients for food and feed applications.”

FeedKind® has been validated over several years after extensive trials across several popular aquaculture species, including seabass, bream, and salmon. Thailand’s Kasetsart University, Thailand, recently found distinct benefits for shrimp, saying FeedKind® promotes strong, healthy growth, while also helping activate shrimp’s immune response to Vibrio, the causative agent of Early Mortality Syndrome.

The JV partners are now focusing on bringing the next phase of the development forward, bringing output to 80,000 tonnes per year. The first material from Calysseo is expected at the turn of the year.